ArticleTranslational oncology2024

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo.

Neil T Conlon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.